IgA nephropathy

Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 16, 2022 - 9:05pm
Income, Private Securities Litigation Reform Act, Food, Research, U.S. Securities and Exchange Commission, Cardiopulmonary bypass, FSGS, Patient, NASDAQ, Vifor Pharma, ROCK2, CYP11B2, Â, COVID-19, Kidney, FDA, IND, CRO, Safety, Degenerative disease, IPO, Therapy, CMO, DGF, Idiopathic pulmonary fibrosis, IPF, Security (finance), Investigational New Drug, GLOBE, Fine chemical, Pharmaceutical industry, IgA nephropathy

UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and reported its financial results for the quarter ended March 31, 2022.

Key Points: 
  • UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and reported its financial results for the quarter ended March31, 2022.
  • As of March31, 2022, Angion had cash and cash equivalents totaling $73.0 million.
  • Contract revenue for the quarter ended March31, 2022 was $1.6 million compared with $0.4 million in the same period in 2021.
  • Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 16, 2022 - 12:30pm
Autoantibody, CEO, KOL, Private Securities Litigation Reform Act, Disease, Infection, IgA nephropathy, U.S. Securities and Exchange Commission, Nasdaq, Degenerative disease, Patient, SLE, BK virus, Therapy, B cell, Viral load, Clinical trial, COVID-19, Proteinuria, Mortality, BK, Quarter, Research, FDA, Immunoglobulin A, Kidney disease, Plasma, Conference, FASN, FAST, Program, B-cell activating factor, Congress, Virus, Safety, HIV disease progression rates, Lupus nephritis, Standard of care, European Renal Association – European Dialysis and Transplant Association, Lupus, Security (finance), Viremia, Polyomaviridae, MD, Vera, GLOBE, Pharmaceutical industry, Online gambling, Cryptocurrency, BKV, Shareholder

Topline results from the study are expected to be presented in the fourth quarter 2022, which we expect will be used to support the initiation of a pivotal Phase 3 clinical trial of atacicept in 2023.

Key Points: 
  • Topline results from the study are expected to be presented in the fourth quarter 2022, which we expect will be used to support the initiation of a pivotal Phase 3 clinical trial of atacicept in 2023.
  • Enrollment in the Phase 2b ORIGIN clinical trial of atacicept remains on track, topline data expected in the fourth quarter 2022.
  • Vera reported approximately $151 million in cash, cash equivalents and marketable securities as of March 31, 2022.
  • Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases.

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

Retrieved on: 
Monday, May 16, 2022 - 12:00pm
PDUFA, Heart Protection Study, PROTECT, Jay Traver, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, New Drug Application, Patient, Priority review, Chronic kidney disease, NASDAQ, Review, Therapy, Proteinuria, FDA, SAN, Immunoglobulin A, NDA, GLOBE, Pharmaceutical industry, IgA nephropathy

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).

Key Points: 
  • SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).
  • For decades people living with IgA nephropathy have had limited treatment options while facing a progression toward end-stage kidney disease.
  • If approved, sparsentan would be the first FDA-approved non-immunosuppressive treatment option for IgA nephropathy, and we aspire to ultimately position sparsentan as a new standard of care, said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics.
  • Sparsentan has been granted Orphan Drug Designation for the treatment of IgAN and FSGS in the U.S. and Europe.

Calliditas Therapeutics Launches an Online Patient Platform

Retrieved on: 
Saturday, May 14, 2022 - 1:00pm
Autoantibody, Kidney bean, Nasdaq Stockholm, Disease, Immunoglobulin A, IgA nephropathy, Nasdaq, Chronic kidney disease, Environment, Barratt, Therapy, Kidney, Nationwide, Caregiver, Mortality, Gut, A, Diagnosis, American depositary receipt, CALT, GLOBE, Online gambling, Pharmaceutical industry, Welander

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.

Key Points: 
  • STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
  • Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation of America commented, IgA nephropathy is a complicated disease that can leave individuals with many unanswered questions.
  • With the launch of IgAN Connect, I am grateful that individuals will have even more resources to embark on this journey.
  • Calliditas common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, May 12, 2022 - 9:20pm
Employment, Primary hyperoxaluria, Company, Nasdaq, Atrasentan, Inducement rule, Chronic kidney disease, Therapy, Financial compensation, LDHA, IgA nephropathy, Kidney, Immunoglobulin A, RNA, GLOBE, Pharmaceutical industry, Chinook

The stock options have a 10-year term and are subject to the terms and conditions of the stock option agreement.

Key Points: 
  • The stock options have a 10-year term and are subject to the terms and conditions of the stock option agreement.
  • The Company granted the stock options as a material inducement to this employee for entering into employment with Chinook Therapeutics, Inc. in accordance with Nasdaq listing Rule 5635(c)(4).
  • Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases.
  • In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases.

Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results

Retrieved on: 
Thursday, May 12, 2022 - 9:01pm
Kidney transplantation, ID, Company, Private Securities Litigation Reform Act, Research, Social media, U.S. Securities and Exchange Commission, Neurodegeneration, Webcast, Cell Transplantation, NASDAQ, Coronavirus, Investor relations, Home After Three Months Away, CD40L, Primate, CD154, Forward-looking statement, Autoimmune disease, Safety, Completeness, Person, LinkedIn, Twitter, ALS, GLOBE, Pharmaceutical industry, Dentistry, Online gambling, IgA nephropathy, Eledone

IRVINE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today reported its first quarter 2022 operating and financial results.

Key Points: 
  • IRVINE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (Eledon) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today reported its first quarter 2022 operating and financial results.
  • Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart in ALS and remain on track to deliver topline results in June 2022.
  • Eledon will hold a conference call today,May 12, 2022,at4:30 pm Eastern Timeto discuss first quarter 2022 results.
  • Follow Eledon Pharmaceuticals on social media: LinkedIn ; Twitter
    This press release contains forward-looking statements that involve substantial risks and uncertainties.

Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022 - 9:00pm
Komodo, CKD, Primary hyperoxaluria, Disease, Research, Urine, Webcast, Kidney disease, Proteinuria, ERA, Cohort, SEC, Chronic kidney disease, Nature, Drug development, Immunoglobulin A, Atrasentan, Therapy, LDHA, Clinical trial, COVID-19, Philippine Council of Evangelical Churches, Board, RNA, Nephrology, GLOBE, Part, FSGS, Patient, ISN, Merck, Focal segmental glomerulosclerosis, Awareness, Alport syndrome, Program, Congress, ETA, CVR, Blood, Nasdaq, SGLT2, Tax, Kidney, Industry, Forward-looking statement, Technology, Board of directors, Pharmaceutical industry, Vaccine, Management, Video game, IgA nephropathy, Chinook, Evotec

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022.
  • In March 2022, Chinook presented an overview of the phase 2 AFFINITY clinical trial at the 4th Annual Chronic Kidney Disease (CKD) Drug Development Summit.
  • In February 2022, Chinook delivered an encore trials-in-progress presentations on the phase 3 ALIGN and phase 2 AFFINITY clinical trials at the ISN World Congress of Nephrology 2022.
  • In March 2022, Chinook presented a detailed overview of the BION-1301 program at the 4th Annual CKD Drug Development Summit.

Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

Retrieved on: 
Monday, May 9, 2022 - 1:00pm
EGFR, Forward-looking statement, Blood, Private Securities Litigation Reform Act, Twitter, U.S. Securities and Exchange Commission, Proteinuria, NASDAQ, GLOBE, CD154, Death, IgA nephropathy, Safety, ESRD, Patient, Autoimmune disease, Cell Transplantation, Urine, Coronavirus, Survival, Budesonide, Person, Diagnosis, Neurodegeneration, Dialysis, CD40L, LinkedIn, Disease, Chronic kidney disease, Autoantibody, ALS, Risk, Social media, Pharmaceutical industry, Vaccine, Eledone

IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today reported that the first patient has been dosed in a Phase 2a study evaluating tegoprubart in patients with IgA Nephropathy (IgAN).

Key Points: 
  • IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today reported that the first patient has been dosed in a Phase 2a study evaluating tegoprubart in patients with IgA Nephropathy (IgAN).
  • "We are pleased to begin our clinical evaluation of tegoprubart in this area of great unmet need and look forward to sharing early results from this Phase 2a study at the end of the year."
  • Eledon is headquartered in Irvine, Calif. For more information, please visit the company's website at www.eledon.com .
  • Follow Eledon Pharmaceuticals on social media: LinkedIn ; Twitter
    This press release contains forward-looking statements that involve substantial risks and uncertainties.

Vera Therapeutics to Present at Upcoming Conferences in May 2022

Retrieved on: 
Thursday, May 5, 2022 - 9:05pm
Standard of care, B-cell activating factor, Virus, BK virus, Immunoglobulin A, Vera, Patient, B cell, Calendar, Lupus nephritis, Degenerative disease, Polyomaviridae, BK, IgA nephropathy, Autoantibody, Therapy, Online shopping, Vaccine

A replay of the event will be available for 30 days and can be accessed by visiting the Investor Calendar section of the Vera Therapeutics website.

Key Points: 
  • A replay of the event will be available for 30 days and can be accessed by visiting the Investor Calendar section of the Vera Therapeutics website.
  • Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases.
  • Veras mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients.
  • In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful.

Travere Therapeutics Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022 - 9:01pm
GAAP, SIMD, HCU, Safety, Caregiver, Irbesartan, Travers Tool, Life, Annual general meeting, Risk, Investor, EGFR, CMA, Mission statement, NASDAQ, Company, Kidney, Patient, FDA, SG, Regulation of tobacco by the U.S. Food and Drug Administration, New Drug Application, PROTECT, Disease, SAN, Therapy, Heart Protection Study, U.S. Securities and Exchange Commission, Society, Private Securities Litigation Reform Act, Immunoglobulin A, Union, Proteinuria, NDA, Research, Security (finance), Cystinuria, International, R, MAA, Vifor Pharma, Acquisition, COVID-19, Table, Maintenance, GLOBE, Food, Trial of the century, Review, Webcast, Income tax, Patent, Cystine, Form 10-K, Pharmaceutical industry, Fine chemical, Lithium, Bank, FSGS, IgA nephropathy

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.

Key Points: 
  • SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.
  • Total other expense, net, for the first quarter of 2022 was $9.8 million, compared to $6.0 million for the same period in 2021.
  • ET to discuss company updates as well as first quarter 2022 financial results.
  • The Company believes that these non-GAAP financial measures are helpful in understanding its past financial performance and potential future results.